How much funding has Creyon Bio raised?

Creyon Bio has raised $20.0M in total funding, most recently a Seed round.

Who are Creyon Bio's investors?

Creyon Bio's investors include DCVC (Data Collab), Lux Capital, Casdin Capital, Alexandria Venture Investments.

When was Creyon Bio founded?

Creyon Bio was founded in 2019.

Where is Creyon Bio headquartered?

Creyon Bio is headquartered in San Diego, California, United States.

What industry is Creyon Bio in?

Creyon Bio operates in Biotech, Artificial Intelligence.

How many employees does Creyon Bio have?

Creyon Bio has 11-50 employees.

Creyon Bio

Redefining what's possible in RNA drug design.

San Diego, United States · Founded 2019 · $20.0M raised

Biotech

Artificial Intelligence

Headquarters: San Diego, California
Employees: 11–50
Founded: 2019
Business Model: B2B

Total Funding: $20.0M
Last Round: $20.0M SeedMar 2022
Rounds: 1

About

Creyon Bio is a nucleic acid drug development company using AI-powered aptamer delivery technology to enable precise, tissue-specific delivery of oligonucleotide therapies. Its proprietary NuclelQ platform leverages purpose-built pharmacology datasets and AI/ML tools to design safer and more effective RNA-targeted therapies for immune-driven diseases, CNS indications, and muscle disorders including late-onset Pompe disease. Founded in 2019, the company has raised over $40 million from investors including DCVC Bio, Lux Capital, and Casdin Capital, and has entered a global collaboration with Eli Lilly.

Summary

Creyon Bio is a Biotech company based in San Diego, United States, founded in 2019. It has raised $20.0M in total across 1 round, most recently a $20.0M Seed round in Mar 2022. Investors include DCVC (Data Collab), Lux Capital and Casdin Capital.